The interaction of dyslipidaemia with glycaemia in an adult population study
- 6 Downloads
Individuals with dysglycaemic are prone to dyslipidaemia. Understanding the dyslipidaemic status of dysglycaemic individuals is essential for monitoring and early prevention. The aim was to assess the control of lipidaemia by glycaemic status in a representative adult population.
A retrospective health examination survey was performed on a sample of adults (n = 3947) in Malta in 2014–6. Sociodemographic data, biochemistry blood tests and anthropometric measurements were gathered. Statistical analysis was performed to evaluate the lipidaemic status and its control across the glycaemic spectrum (normoglycemic, impaired fasting glucose individuals, new diabetics and known diabetics).
The prevalence of uncontrolled dyslipidaemia was 7.75% (CI 95%: 6.69–8.63), among whom 6.97% (CI 95%: 6.21–7.81) were naïve dyslipidaemic. A progressive elevation in both LDL-C and total cholesterol but not triglycerides was present among uncontrolled dyslipidaemia individuals across the glycaemic spectrum. Global dyslipidaemia was present in 19.26% (CI 95%: 18.05–20.52) of the total general population and in 46.59% (CI 95%: 40.49–52.69%) of known diabetics. Most individuals irrespective of lipid status were normoglycaemic.
Dyslipidaemia occurs in the presence of insulin resistance. Dyslipidaemia predominated in the normoglycaemic state irrespective of statins use, indicating the need to manage dyslipidaemia prior to dysglycaemia.
KeywordsHyperlipidaemia Diabetes mellitus, type 2 Insulin resistance, policy Epidemiology Malta
The in-kind support and encouragement of the Parliamentary Secretariat for Health of the Government of Malta is gratefully acknowledged.
The authors are extremely grateful for the strong financial support from the University of Malta (through the Medical School and Research Innovative Development Trust department) and from the Alfred Mizzi Foundation as major sponsors, as well as others, including Atlas Health Insurance (Malta). None of the funding sources had any role in the research design, the data collection, the analysis and interpretation of the data or in the preparation of the article.
Compliance with ethical standards
Conflict of interests
The authors declare that they have no conflict of interest.
- 2.Samatha P, Venkateswarlu MSPV. Lipid profile levels in type 2 diabetes mellitus from the tribal population of Adilabad in Andhra Pradesh, India. J Clin diagnostic Res. 2012;6:590–2.Google Scholar
- 9.Daniel MJ. Lipid management in patients with type 2 diabetes. Am Heal drug benefits. 2011;4:312–22.Google Scholar
- 10.Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Rev Port Cardiol. 2006;25:865–8.Google Scholar
- 16.Cuschieri S, Vassallo J, Calleja N, et al. The diabesity health economic crisis-the size of the crisis in a European island state following a cross-sectional study. Arch Public Heal. 2016;74. https://doi.org/10.1186/s13690-016-0164-6.
- 17.Cuschieri S, Malta MJ. Mediterranean diabetes hub – A journey through the years. Malta Med J. 26.Google Scholar
- 19.Cuschieri S, Vassallo J, Calleja N, Pace NMJ. Diabetes, pre-diabetes and their risk factors in Malta: a study profile of national cross-section prevalence study. Glob Heal Epidemiol Genomics. 2016;1. https://doi.org/10.1017/gheg.2016.18.
- 20.Hockley T, Gemmill M. European Cholesterol Guidelines Report https://policy-centre.com/wp-content/uploads/2017/04/European-Cholesterol-Guidelines07.pdf (accessed 5 November 2017).Google Scholar
- 22.American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1: S13–S22.Google Scholar
- 23.WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ. 2013:102.Google Scholar
- 24.(UK) NCGC. Statins for the primary and secondary prevention of CVD https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071769/ (2014, accessed 6 November 2017).
- 30.Buse K, Tanaka SHS. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Heal. 2017;13. https://doi.org/10.1186/s12992-017-0255-3.